Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451

This RCT (n=834) found maintenance therapy with nivolumab plus ipilimumab did not prolong overall survival for patients who did not progress on first-line chemotherapy vs placebo ([HR], 0.92; 95% CI 0.75 to 1.12; P=0.37; median, 9.2v9.6 months). There were no new safety signals.

Source:

Journal of Clinical Oncology